Illumina

Illumina is a developer, manufacturer, and marketer of life science tools and integrated systems for large-scale analysis of genetic variation and function. Illumina has developed a line of DNA sequencing technology products that address the scale of experimentation and breadth of functional analysis to advance disease research, drug development, and the development of molecular tests.

Illumina Company Profile 

 

President & CEO: Francis deSouza

CEO photo:

illumina CEO Francis deSouza photo

Website: www.illumina.com

Ticker symbol: ILMN

Headquarters: San Diego, CA

Illumina employees: 5,500+ globally

Revenues: $2.4 Billion USD in 2016

Founded: 1998

Founders: Larry Bock, Anthony Czarnik, David Walt, Mark Chee, John Stuelpnagel

 

Illumina News 

OrigiMed is a Shanghai, China-based company focusing on the development of new oncology assays.

Illumina is working on further reducing turnaround time of the analysis and on detecting structural variants and repeat expansions.

Illumina has extended a supply agreement with Foundation until 2023 and developed an automated metagenomics workflow with PerkinElmer.

Illumina said the acquisition will help enable a standardized process for sequencing and analysis and speed up the time it take to get a result.

The firm said momentum from the launch of its kidney transplant test Allosure drove the overall revenue increase.

CareDx has paid Illumina a $5 million initial payment and will pay royalties in the mid-single to low-double digits on sales of future commercialized products.

Luna DNA, which offers a cryptocurrency to reward people for sharing biological and medical data with researchers, has raised $4 million to date.

The effort aims to sequence at least 150 animals, plants, and microbes selected for their potential benefits to Canada in the next three years.

Illumina launched the accelerator program in 2014 to provide biotech startups with investment capital, genomics expertise, and other resources.

The company said that recent regulatory and reimbursement decisions have been favorable and will help spur adoption of clinical NGS testing.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.